The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors

[1]  Yi Wang,et al.  Scalable molecular dynamics on CPU and GPU architectures with NAMD. , 2020, The Journal of chemical physics.

[2]  M. Ohh,et al.  NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS–MAPK Pathway in Neuroblastoma , 2020, Cancer Research.

[3]  A. Gorfe,et al.  Conformational and Dynamical Effects of Tyr32 Phosphorylation in K-Ras: Molecular Dynamics Simulation and Markov State Models Analysis. , 2019, The journal of physical chemistry. B.

[4]  Amit K. Gupta,et al.  Multi‐target, ensemble‐based virtual screening yields novel allosteric KRAS inhibitors at high success rate , 2019, Chemical biology & drug design.

[5]  P. Hammerman,et al.  SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors , 2019, Molecular Cancer Therapeutics.

[6]  H. Briem,et al.  Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction , 2019, Proceedings of the National Academy of Sciences.

[7]  S. Phillips,et al.  Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds , 2019, Proceedings of the National Academy of Sciences.

[8]  M. Ikura,et al.  Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation , 2019, Nature Communications.

[9]  R. Sachidanandam,et al.  SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors , 2019, Cell reports.

[10]  R. Beroukhim,et al.  Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition , 2018, Nature Medicine.

[11]  B. Neel,et al.  SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models. , 2018, Cancer discovery.

[12]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[13]  W. Birchmeier,et al.  Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase , 2018, Nature Medicine.

[14]  R. Bernards,et al.  SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo , 2018, Nature Medicine.

[15]  James M. McFarland,et al.  Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2 , 2018, Nature Medicine.

[16]  M. Lawrence,et al.  SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors , 2018, Nature Medicine.

[17]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[18]  I. Tsigelny,et al.  Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer. , 2018, Cancer discovery.

[19]  M. Schaeffer,et al.  KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer , 2016, Oncotarget.

[20]  M. Tiseo,et al.  Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. , 2016, Translational lung cancer research.

[21]  Ping Zhu,et al.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases , 2016, Nature.

[22]  Ash A. Alizadeh,et al.  Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients , 2016, Nature Communications.

[23]  D. Xiu,et al.  Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis , 2016, World Journal of Surgical Oncology.

[24]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[25]  E. Assenat,et al.  KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma , 2016, Clinical and Translational Gastroenterology.

[26]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[27]  S. Dhanasekaran,et al.  KRAS Engages AGO2 to Enhance Cellular Transformation. , 2016, Cell reports.

[28]  B. Raught,et al.  Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis , 2015, Nature Communications.

[29]  Jen Jen Yeh,et al.  Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma , 2015, Nature Genetics.

[30]  G. Montelione,et al.  The RAS-Binding Domain of Human BRAF Protein Serine/Threonine Kinase Exhibits Allosteric Conformational Changes upon Binding HRAS. , 2015, Structure.

[31]  John C. Hunter,et al.  Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations , 2015, Molecular Cancer Research.

[32]  K. Rau,et al.  A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[34]  R. Nussinov,et al.  Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. , 2015, Structure.

[35]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[36]  Woonghee Lee,et al.  NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy , 2014, Bioinform..

[37]  Lin Zhang,et al.  Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer , 2014, Genes & diseases.

[38]  Maria G Khrenova,et al.  Modeling the role of G12V and G13V Ras mutations in the Ras-GAP-catalyzed hydrolysis reaction of guanosine triphosphate. , 2014, Biochemistry.

[39]  B. Raught,et al.  Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation , 2014, Proceedings of the National Academy of Sciences.

[40]  C. Wells,et al.  Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase , 2014, Journal of medicinal chemistry.

[41]  John C Hunter,et al.  In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C , 2014, Proceedings of the National Academy of Sciences.

[42]  Steven A. Curley,et al.  RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.

[43]  Mitsuhiko Ikura,et al.  NMR-based functional profiling of RASopathies and oncogenic RAS mutations , 2013, Proceedings of the National Academy of Sciences.

[44]  Tetsuya Nakamura,et al.  The acquisition of malignant potential in colon cancer is regulated by the stabilization of Atonal homolog 1 protein. , 2013, Biochemical and biophysical research communications.

[45]  Alexander D. MacKerell,et al.  Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. , 2012, Journal of chemical theory and computation.

[46]  M. Ikura,et al.  Probing the GTPase cycle with real-time NMR: GAP and GEF activities in cell extracts. , 2012, Methods.

[47]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[48]  A. Fernández-Medarde,et al.  Ras in cancer and developmental diseases. , 2011, Genes & cancer.

[49]  K. Rauen,et al.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. , 2009, Current opinion in genetics & development.

[50]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[51]  Özkan Yildiz,et al.  Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II , 2008, The EMBO journal.

[52]  J. Salles,et al.  The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway. , 2008, Cellular signalling.

[53]  Alfred Wittinghofer,et al.  GEFs and GAPs: Critical Elements in the Control of Small G Proteins , 2007, Cell.

[54]  M. Krasnow,et al.  Sprouty proteins are in vivo targets of Corkscrew/SHP-2 tyrosine phosphatases , 2006, Development.

[55]  J. Kuriyan,et al.  High yield bacterial expression of active c‐Abl and c‐Src tyrosine kinases , 2005, Protein science : a publication of the Protein Society.

[56]  J. Salles,et al.  A Novel Role for Gab1 and SHP2 in Epidermal Growth Factor-induced Ras Activation* , 2005, Journal of Biological Chemistry.

[57]  Alexander D. MacKerell,et al.  Improved treatment of the protein backbone in empirical force fields. , 2004, Journal of the American Chemical Society.

[58]  M. Hayman,et al.  Molecular Mechanism for a Role of SHP2 in Epidermal Growth Factor Receptor Signaling , 2003, Molecular and Cellular Biology.

[59]  J Kuriyan,et al.  Structure-based Mutagenesis Reveals Distinct Functions for Ras Switch 1 and Switch 2 in Sos-catalyzed Guanine Nucleotide Exchange* , 2001, The Journal of Biological Chemistry.

[60]  T P Straatsma,et al.  The arginine finger of RasGAP helps Gln-61 align the nucleophilic water in GAP-stimulated hydrolysis of GTP , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Phillip T. Hawkins,et al.  Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.

[62]  D. Singel,et al.  Structural changes induced in p21Ras upon GAP-334 complexation as probed by ESEEM spectroscopy and molecular-dynamics simulation. , 2000, Structure.

[63]  A. Warshel,et al.  How does GAP catalyze the GTPase reaction of Ras? A computer simulation study. , 2000, Biochemistry.

[64]  M. Ivan,et al.  Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein , 2000, Nature Cell Biology.

[65]  P. Hawkins,et al.  Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. , 2000, Cell.

[66]  L. Alberghina,et al.  Characterization and Properties of Dominant-negative Mutants of the Ras-specific Guanine Nucleotide Exchange Factor CDC25Mm * , 1999, The Journal of Biological Chemistry.

[67]  J Zeng,et al.  Molecular dynamics simulations of the Ras:Raf and Rap:Raf complexes , 1999, Proteins.

[68]  John Kuriyan,et al.  The structural basis of the activation of Ras by Sos , 1998, Nature.

[69]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[70]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[71]  C. Der,et al.  Involvement of the Switch 2 Domain of Ras in Its Interaction with Guanine Nucleotide Exchange Factors (*) , 1996, The Journal of Biological Chemistry.

[72]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[73]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[74]  M. Klein,et al.  Constant pressure molecular dynamics algorithms , 1994 .

[75]  C. Walsh,et al.  Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  T. Darden,et al.  Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: an experimental and theoretical study. , 1994, Biochemistry.

[77]  Jonathan A. Cooper,et al.  A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase , 1994, Molecular and cellular biology.

[78]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[79]  I. Schlichting,et al.  Mutations of Ha‐ras p21 that define important regions for the molecular mechanism of the SDC25 C‐domain, a guanine nucleotide dissociation stimulator. , 1992, The EMBO journal.

[80]  W. Kabsch,et al.  Refined crystal structure of the triphosphate conformation of H‐ras p21 at 1.35 A resolution: implications for the mechanism of GTP hydrolysis. , 1990, The EMBO journal.

[81]  D. A. Brown,et al.  [Presynaptic and postsynaptic mechanisms of phosphoinositide metabolites]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[82]  Baroni,et al.  Conjugate gradient minimization of the energy functional: A new method for electronic structure calculation. , 1989, Physical review. B, Condensed matter.

[83]  C. Der,et al.  Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. , 1982, Proceedings of the National Academy of Sciences of the United States of America.